Vaccibody AS announced today vaccination of the first patient in its phase IIa study – an exploratory, open-label, multicenter study with VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16).
The phase I part of...

Vaccibody AS announces today that inclusion of patients in the expansion phase (phase IIa) of its multicentre trial VB C-01 can be initiated as the company was informed by Paul-Ehrlich Institut („PEI“), the German regulatory authorities, that an amendment to the IMPD (Investigational Medicinal Product...

Reference is made to the press release published by Vaccibody AS (“Vaccibody” or the “Company”) on 9 December 2016 regarding the contemplated private placement (the “Private Placement”) of new shares (the “Offer Shares”) in the Company.
The Board of Directors of the Company is pleased to...

Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their review of the interim analysis of the results from the phase I dosing part of the multicentre trial VB C-01. The two committees recommended continuation...

Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

Therapeutic vaccine company Vaccibody today announced that it has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour-...